2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

Adarsh Bhimraj; Yngve Falck-Ytter; Lindsey R. Baden; Roger Bedimo; Kelly Cawcutt; Vincent Chi Chung Cheng; Kara W. Chew; Kathleen Chiotos; Eric S. Daar; Amy L. Dzierba; David V. Glidden; Erica J. Hardy; Steven Johnson; Arthur Y. Kim; Jonathan Z. Li; Christine Macbrayne; Greg S. Martin; Nandita Nadig; Mari M. Nakamura; Jeffrey C. Pearson; Laura Riley; Robert W. Shafer; Shmuel Shoham; Amy Hirsch Shumaker; Pablo Tebas; Phyllis C. Tien; Jennifer Loveless; Rebecca L. Morgan; Rajesh T. Gandhi

doi:10.1093/cid/ciaf424

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

Adarsh Bhimraj, Yngve Falck-Ytter, Lindsey R. Baden, Roger Bedimo, Kelly Cawcutt, Vincent Chi Chung Cheng, Kara W. Chew, Kathleen Chiotos, Eric S. Daar, Amy L. Dzierba, David V. Glidden, Erica J. Hardy, Steven Johnson, Arthur Y. Kim, Jonathan Z. Li, Christine Macbrayne, Greg S. Martin, Nandita Nadig, Mari M. Nakamura, Jeffrey C. PearsonLaura Riley, Robert W. Shafer, Shmuel Shoham, Amy Hirsch Shumaker, Pablo Tebas, Phyllis C. Tien, Jennifer Loveless, Rebecca L. Morgan, Rajesh T. Gandhi

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

As the first part of several focused updates to the clinical practice guideline on the treatment and management of COVID-19 in adults, children, and pregnant people, developed by the Infectious Diseases Society of America, the panel presents four new recommendations. These recommendations include pre-exposure prophylaxis for immunocompromised persons and treatment of severe or critical COVID-19. The panel's recommendations are based upon evidence derived from systematic literature reviews and adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach.

Original language	English (US)
Journal	Clinical Infectious Diseases
Volume	81
DOIs	https://doi.org/10.1093/cid/ciaf424
State	Published - Oct 15 2025

Keywords

COVID-19
abatacept
infliximab
pemivibart
vilobelimab

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/ciaf424

Fingerprint

Dive into the research topics of '2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness'. Together they form a unique fingerprint.

Cite this

Bhimraj, A., Falck-Ytter, Y., Baden, L. R., Bedimo, R., Cawcutt, K., Cheng, V. C. C., Chew, K. W., Chiotos, K., Daar, E. S., Dzierba, A. L., Glidden, D. V., Hardy, E. J., Johnson, S., Kim, A. Y., Li, J. Z., Macbrayne, C., Martin, G. S., Nadig, N., Nakamura, M. M., ... Gandhi, R. T. (2025). 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness. Clinical Infectious Diseases, 81. https://doi.org/10.1093/cid/ciaf424

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness. / Bhimraj, Adarsh; Falck-Ytter, Yngve; Baden, Lindsey R. et al.
In: Clinical Infectious Diseases, Vol. 81, 15.10.2025.

Research output: Contribution to journal › Article › peer-review

Bhimraj, A, Falck-Ytter, Y, Baden, LR, Bedimo, R, Cawcutt, K, Cheng, VCC, Chew, KW, Chiotos, K, Daar, ES, Dzierba, AL, Glidden, DV, Hardy, EJ, Johnson, S, Kim, AY, Li, JZ, Macbrayne, C, Martin, GS, Nadig, N, Nakamura, MM, Pearson, JC, Riley, L, Shafer, RW, Shoham, S, Shumaker, AH, Tebas, P, Tien, PC, Loveless, J, Morgan, RL & Gandhi, RT 2025, '2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness', Clinical Infectious Diseases, vol. 81. https://doi.org/10.1093/cid/ciaf424

Bhimraj A, Falck-Ytter Y, Baden LR, Bedimo R, Cawcutt K, Cheng VCC et al. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness. Clinical Infectious Diseases. 2025 Oct 15;81. doi: 10.1093/cid/ciaf424

Bhimraj, Adarsh ; Falck-Ytter, Yngve ; Baden, Lindsey R. et al. / 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19 : Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness. In: Clinical Infectious Diseases. 2025 ; Vol. 81.

@article{97876f88abcc401a9e971300cb70b77a,

title = "2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness",

abstract = "As the first part of several focused updates to the clinical practice guideline on the treatment and management of COVID-19 in adults, children, and pregnant people, developed by the Infectious Diseases Society of America, the panel presents four new recommendations. These recommendations include pre-exposure prophylaxis for immunocompromised persons and treatment of severe or critical COVID-19. The panel's recommendations are based upon evidence derived from systematic literature reviews and adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach.",

keywords = "COVID-19, abatacept, infliximab, pemivibart, vilobelimab",

author = "Adarsh Bhimraj and Yngve Falck-Ytter and Baden, \{Lindsey R.\} and Roger Bedimo and Kelly Cawcutt and Cheng, \{Vincent Chi Chung\} and Chew, \{Kara W.\} and Kathleen Chiotos and Daar, \{Eric S.\} and Dzierba, \{Amy L.\} and Glidden, \{David V.\} and Hardy, \{Erica J.\} and Steven Johnson and Kim, \{Arthur Y.\} and Li, \{Jonathan Z.\} and Christine Macbrayne and Martin, \{Greg S.\} and Nandita Nadig and Nakamura, \{Mari M.\} and Pearson, \{Jeffrey C.\} and Laura Riley and Shafer, \{Robert W.\} and Shmuel Shoham and Shumaker, \{Amy Hirsch\} and Pablo Tebas and Tien, \{Phyllis C.\} and Jennifer Loveless and Morgan, \{Rebecca L.\} and Gandhi, \{Rajesh T.\}",

year = "2025",

month = oct,

day = "15",

doi = "10.1093/cid/ciaf424",

language = "English (US)",

volume = "81",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19

T2 - Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

AU - Bhimraj, Adarsh

AU - Falck-Ytter, Yngve

AU - Baden, Lindsey R.

AU - Bedimo, Roger

AU - Cawcutt, Kelly

AU - Cheng, Vincent Chi Chung

AU - Chew, Kara W.

AU - Chiotos, Kathleen

AU - Daar, Eric S.

AU - Dzierba, Amy L.

AU - Glidden, David V.

AU - Hardy, Erica J.

AU - Johnson, Steven

AU - Kim, Arthur Y.

AU - Li, Jonathan Z.

AU - Macbrayne, Christine

AU - Martin, Greg S.

AU - Nadig, Nandita

AU - Nakamura, Mari M.

AU - Pearson, Jeffrey C.

AU - Riley, Laura

AU - Shafer, Robert W.

AU - Shoham, Shmuel

AU - Shumaker, Amy Hirsch

AU - Tebas, Pablo

AU - Tien, Phyllis C.

AU - Loveless, Jennifer

AU - Morgan, Rebecca L.

AU - Gandhi, Rajesh T.

PY - 2025/10/15

Y1 - 2025/10/15

N2 - As the first part of several focused updates to the clinical practice guideline on the treatment and management of COVID-19 in adults, children, and pregnant people, developed by the Infectious Diseases Society of America, the panel presents four new recommendations. These recommendations include pre-exposure prophylaxis for immunocompromised persons and treatment of severe or critical COVID-19. The panel's recommendations are based upon evidence derived from systematic literature reviews and adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach.

AB - As the first part of several focused updates to the clinical practice guideline on the treatment and management of COVID-19 in adults, children, and pregnant people, developed by the Infectious Diseases Society of America, the panel presents four new recommendations. These recommendations include pre-exposure prophylaxis for immunocompromised persons and treatment of severe or critical COVID-19. The panel's recommendations are based upon evidence derived from systematic literature reviews and adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach.

KW - COVID-19

KW - abatacept

KW - infliximab

KW - pemivibart

KW - vilobelimab

UR - https://www.scopus.com/pages/publications/105027654578

UR - https://www.scopus.com/inward/citedby.url?scp=105027654578&partnerID=8YFLogxK

U2 - 10.1093/cid/ciaf424

DO - 10.1093/cid/ciaf424

M3 - Article

C2 - 40757658

AN - SCOPUS:105027654578

SN - 1058-4838

VL - 81

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

ER -

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this